Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADAPTIVE PHASE 2/3 STUDY OF THE EFFICACY OF LAU-7b IN THE TREATMENT OF ADULTS WITH LONG COVID AND MODERATE TO SEVERE SYMPTOMS

NCT05999435 is registered in ClinicalTrials.gov with Laurent Pharmaceuticals Inc. as lead sponsor.

NCT NCT05999435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05999435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADAPTIVE PHASE 2/3 STUDY OF THE EFFICACY OF LAU-7b IN THE TREATMENT OF ADULTS WITH LONG COVID AND MODERATE TO SEVERE SYMPTOMS
Lead sponsor
Laurent Pharmaceuticals Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
November 15, 2023
Completion date
November 30, 2024
Enrollment
272 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

long covid